Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL-1.
Rabe KF., Pavord ID., Castro M., Wechsler ME., Daizadeh N., Kapoor U., Ortiz B., Radwan A., Johnson RR., Rowe PJ., Deniz Y., Jacob-Nara JA.
Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL−1). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb